Regulatory and Nonclinical Considerations for the Development of CNS/Neurology Therapeutics

  • You must log in to register
    • Nonmember - $350
    • Full Member - $225
    • Associate Member - $225
    • Emeritus Member - $225
    • Government Associate Member - $225
    • Government Full Member - $225
    • Postdoctoral Researcher/Transitional Member - $125
    • Student Member - $125

To further its mission to educate, lead, and serve, the American College of Toxicology is proud to offer an eLearning Seminar focused on development of CNS/Neurology Therapeutics. These four modules are intended to provide insight into the development of therapeutics for CNS/Neurology diseases, focusing on the regulatory and nonclinical considerations for safety assessment of therapies encompassing standard and novel modalities, including small molecules, biologics, anti-sense oligonucleotides (ASOs)/miRNA, and advanced cell and gene therapies. 

These modules feature presentations by recognized experts in the field. Modules are available for purchase as a set. Once the live module presentations conclude, registrants will have on-demand access to the modules for 30 days from the time each archive is first accessed. Each module is approximately 90 minutes.

Disclaimer:
This seminar reflects the views of the speaker and should not be construed to represent the views or policies of the American College of Toxicology. Examples presented in this seminar may have required unique strategies that do not necessarily apply to other modalities or situations. Regulatory guidelines and best practices are constantly evolving, and the viewer is encouraged to independently confirm their understanding with what was presented in this seminar.

  • Contains 3 Component(s) Recorded On: 02/15/2024

    CNS/Neurology Therapeutics Series

    image
    image


    According to 21 CFR Part 312.23 (a)(8) of the US regulations, sufficient information derived from nonclinical pharmacology and toxicology studies is needed in order to support the decision that a clinical trial in human subjects is reasonably safe and scientifically feasible to conduct. The data resulting from the nonclinical studies should support scientific proof-of-principle and safety for the administration of the investigational product in the specified clinical population. In addition, nonclinical studies help guide the design of certain elements of a clinical trial. The development of cell and gene therapies for neurological indications over recent decades has demonstrated the potential clinical benefits of these therapies for this heterogeneous group of disorders. However, there remain significant questions, including the risks associated with these products that are not understood. Thus, a comprehensive nonclinical characterization of novel cell and gene therapy products and their associated risks are critical for the safe conduct of future clinical trials. This presentation will provide a general overview of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products (OTP), the existing regulatory framework, including avenues for interactive communications, and resources to guide stakeholders in the nonclinical assessment of the safety and activity of cell and gene therapy products for neurological indications.

    Mondona McCann, PhD

    Mondona McCann, PhD

    Pharmacology/Toxicology Reviewer

    US FDA

    Dr. Mondona McCann is a Pharmacology/Toxicology reviewer in the U.S. Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research (CBER)’s Office of Therapeutic Products. She received her PhD in neuroscience from Georgetown University; her thesis research investigated the impact of organochlorine environmental toxicants on astrocytic function and metabolism. Following her graduate studies, Dr. McCann completed her post-doctoral training at the FDA where she conducted research on the efficacy and safety of IL13Rα2 CAR T cell therapy for glioblastoma and pancreatic cancer. At the completion of her fellowship, Dr. McCann joined the Office of Pharmacology and Toxicology, where she now focuses on the review of nonclinical toxicology and pharmacology data to support the safety of a variety of products including cell and gene therapies, tissue engineered products, and tumor vaccines.

  • Contains 3 Component(s) Recorded On: 03/21/2024

    CNS/Neurology Therapeutics Series

    image
    image


    Nonclinical Development of Onasemnogene Abeparvovec: Challenges and Translational Clinical Experience. The use of gene therapies as a modality to treat rare monogenic diseases continues to increase as they represent a novel approach to treat, and potentially cure, many of these conditions, including rare CNS diseases. Most of these therapies have employed viral vectors as vehicles for delivering therapeutic genes. Recombinant adeno-associated virus (rAAV)-based vectors are frequently used based on their characteristics of being nonpathogenic and replication-deficient and have a transduction profile that results in stable and prolonged transgene expression in nondividing target cells. OAV101 (onasemnogene abeparvovec) is an rAAV-based gene therapy indicated for the treatment of patients with spinal muscular atrophy (SMA) with biallelic mutations in the survival motor neuron 1 (SMN1) gene. First approved by the FDA in May 2019, OAV101(currently marketed as Zolgensma®) has demonstrated substantial clinical efficacy and relative safety in SMA patients following a single IV dose. To ensure that the benefits of OAV101 can be accessible to a significant segment of the SMA patient pool, intrathecal (IT) OAV101 is currently being developed for late-onset SMA patients aged 2 to 18 years. This talk will focus on the nonclinical program developed to support the initiation of clinical trials following IV infusion or IT injection of OAV101. In addition to the proof-of-concept efficacy studies in SMNΔ7 mice and an induced porcine model of SMA, a toxicology program consisting of single-dose integrated toxicity and biodistribution, tolerability, and investigative studies in neonatal mice and juvenile cynomolgus monkeys supported the clinical administration of OAV101. Potential safety risks such as hepatotoxicity, cardiotoxicity, DRG toxicity, immunogenicity, insertional mutagenesis, and tumorigenicity based on OAV101 nonclinical studies as well as literature on other AAV-based gene therapies will be discussed with an emphasis on DRG toxicity and efforts made to better understand the pathogenesis. Operational challenges for nonclinical studies, as well as the translation of nonclinical findings in the clinical setting, will also be addressed, including measures for clinical trial monitoring.

    Francis Tukov, PhD, DVM, DABT

    Francis Tukov, PhD, DVM, DABT

    Director of Preclinical Safety Assessment

    Novartis Pharmaceuticals Corporation

    Dr. Francis Tukov is an experienced board-certified toxicologist with several years of experience in preclinical drug development spanning several therapeutic areas, including Gene Therapy. Since 2019, Dr. Tukov has been leading all Preclinical safety efforts supporting the development of IV onasemnogene abeparvovec (Zolgensma®), the first replacement gene therapy product for the treatment of spinal muscular atrophy. Dr. Tukov continues to lead the preclinical safety activities related to Zolgensma post-marketing and the development of Intrathecal (IT) onasemnogene abeparvovec and other gene therapy-related projects at Novartis. Dr. Tukov is currently a Director of Preclinical Safety Assessment in Novartis Institutes for Biomedical Research (NIBR). He has prior experience as a Study Director/Study Monitor for nonclinical toxicology studies in major disease areas. Francis received a DVM degree in 1995 and obtained a PhD in Pharmacology/Toxicology in 2003.

  • Contains 3 Component(s) Recorded On: 04/25/2024

    CNS/Neurology Therapeutics Series

    image
    image


    Nusinersen has been evaluated in a nonclinical program to support treatment of spinal muscular atrophy (SMA) using lumbar intrathecal (IT) administration. SMA is an autosomal recessive neuromuscular disease that primarily affects infants and children and is characterized by degeneration of the motor neurons in the spinal cord. Deletions in the survival motor neuron gene (SMN1) result in loss of SMN protein and eventual death of motor neurons. A duplicate gene, SMN2, is not functional due to a splicing defect that skips exon 7 and results in truncated SMN protein. Nusinersen is a fully 2'-O-methoxyethyl modified phosphorothioate antisense oligonucleotide designed to bind to SMN2 pre-mRNA and facilitate inclusion of exon 7, resulting in full-length SMN protein.

    PK studies established the minimum tissue concentration that increased exon 7 in mRNA in transgenic mice (2 to 10 µg/g), and the half-life in monkey CNS tissue (~150 days). Toxicology studies included a single-dose IT study in cynomolgus monkeys, 14-week and 53-week repeat-dose IT toxicity studies in juvenile monkeys, 13-week SC study in juvenile CD-1 mice, and SC reproductive toxicity studies in CD-1 mice and NZW rabbits. Genetic toxicology studies (Ames test, chromosomal aberration, mouse micronucleus) were negative. The monkey was chosen for repeat-dose IT toxicology studies and a 53-week study in monkeys established loading and maintenance dose regimen, used to maximize CSF and CNS tissue exposure. Animals received 5 weekly IT doses at 0.3, 1, and 4 mg/dose followed by dosing every 6 weeks (total of 13 IT doses), with a NOAEL at the high dose (4 mg/dose). In clinical studies, infants received 4 loading doses followed by maintenance doses once every 4 months. Safety margins were based on the approximate 10-fold difference in CSF volume between monkeys and humans and the total cumulative yearly dose. The NOAEL of 4 mg/dose (administered 13 times/year) converts to a total human equivalent dose of 520 mg/year, and provides a safety margin of 14-fold compared to the chronic yearly maintenance dose of 36 mg/year in patients.

    Scott Henry, PhD

    Scott Henry, PhD

    Vice President of Nonclinical Development

    Ionis Pharmaceuticals, Inc.

    Dr. Scott Henry received a PhD in Biochemistry from North Dakota State University in 1991, studying the phosphorylation and regulation of the glycogen synthesis pathway in the heart. Following his PhD, he was a postdoctoral fellow at Parke Davis in Ann Arbor, Michigan, in the Department of Toxicology until 1993. He then joined Ionis Pharmaceuticals, Inc. as a Senior Scientist in the department of toxicology. Along with a team of dedicated colleagues, he has characterized and studied the mechanisms of various toxicities that include the effects of oligonucleotide treatment on clotting time prolongation, alternative complement pathway activation, proinflammatory effects in rodents, platelet alterations and the effects related to the accumulation of oligonucleotide in kidney. Now as Vice President of Nonclinical Development at Ionis Pharmaceuticals, Inc. he has participated in the development of approximately 8 different phosphorothioate oligodeoxynucleotides and over 30 different 2’-MOE modified phosphorothioate oligonucleotides.

  • Contains 3 Component(s) Recorded On: 05/16/2024

    CNS/Neurology Therapeutics Series

    image
    image


    Part 1: Development of Biologics for CNS Diseases

    Nonclinical Safety Assessment of Galcanezumab, a CGRP Monoclonal Antibody for the Treatment of Migraine. Emgality® (galcanezumab) is included as a case study of the nonclinical development of biologics for CNS diseases. Galcanezumab is a humanized IgG4 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand with high affinity and selectivity and blocks its binding to the receptor. Elevated blood concentrations of CGRP, a potent vasodilator, have been associated with migraine attacks. Galcanezumab was approved by the US FDA in 2018 and is marketed under the tradename “Emgality®”, for the preventive treatment of migraine and for treatment of episodic cluster headache in the US.

    The nonclinical safety assessment for galcanezumab was designed and conducted according to regulatory guidance (e.g., ICH S5, S6) and GLP guidelines. Galcanezumab is pharmacologically active in rats and rabbits, and the CGRP sequence in monkeys is identical to that in humans. The high doses in the toxicology studies were selected according to ICH S6 criteria: saturation of PD and exposures ̴10X in excess of human recommended doses. The clinical route of administration (subcutaneous) was used, and the dose regimens (QW or more frequently) were chosen to maintain exposure over the treatment periods.

    The presentation will focus on the nonclinical safety package consisting of: 1) repeated-dose toxicology studies in rats and monkeys (SC, QW) up to 6 months, with safety pharmacology parameters (CNS, Respiratory, and Cardiovascular, CV) incorporated in the monkey studies; 2) a full developmental and reproductive toxicology package in rats including male fertility, female fertility, and early embryonic development, embryofetal development (also rabbits), and pre- and postnatal development; and 3) a juvenile toxicology study in rats. Genetic toxicology studies were not required, and carcinogenicity was assessed using a weight-of-evidence evaluation. Dose selection for initial clinical trials was based on in vitro characterization (binding affinity, selectivity, and functionality of binding to CGRP) and an in vivo model of capsaicin-induced increases in dermal blood flow (a PD biomarker of CGRP pathway modulation). Of topical interest to regulators were: 1) high dose selection/justification; and 2) the impact of long-term antagonism of CGRP in humans, particularly in patients with CV risk factors (a theoretical concern considered low based on comprehensive reviews of the literature and data).

    Part 2: The Art of CNS Drug Development: Delivery Strategies, Neurotoxicology Endpoints, and Regulatory Considerations

    The session will present and discuss central nervous system (CNS) drug delivery in preclinical species along with toxicology, translational, and regulatory considerations relevant to these specialized modalities. Fundamental and advanced neurotoxicity endpoints will be reviewed and contrasted as early and late drug development phases are presented. The session will address neurotoxicology concepts that may serve to design or interpret toxicology studies with CNS delivery.

    Simon Authier, DVM, MSc, MBA, PhD, DSP

    Simon Authier, DVM, MSc, MBA, PhD, DSP

    Executive Director of Scientific Innovation and Partnerships

    Charles River Laboratories

    Dr. Simon Authier obtained a Doctor of Veterinary Medicine degree from the University of Montreal and specialized in nonclinical studies after completing a PhD in nonclinical pharmacology. He then completed an MBA in corporate finance and management. Dr. Authier is an Executive Director of Scientific Innovation and Partnerships at Charles River Laboratories, where he leads drug development programs across a broad range of modalities. He has been an invited speaker at various scientific conferences, including the American College of Toxicology, the Safety Pharmacology Society, the Japanese Society of Safety Pharmacology, the American Association of Laboratory Animal Science, and the US Food and Drug Administration. Dr. Authier is an Associate Professor at the Faculty of Veterinary Medicine at the University of Montreal, where he is involved with clinical immunology and pharmacology, and he has authored more than 150 peer-reviewed articles and book chapters. To date, Dr. Authier has provided scientific overviews for more than 1,400 nonclinical studies for small molecules, biologics, and cell therapies. He is a past President of the Safety Pharmacology Society (SPS), is a board-certified safety pharmacologist (DSP), and currently serves as the ACT Secretary. Over the years, he has volunteered and participated in various ACT initiatives, including educational sessions.

    Lorrene A. Buckley, PhD, DABT, ATS

    Lorrene A. Buckley, PhD, DABT, ATS

    Vice President

    Eli Lilly & Company

    Dr. Lorrene Buckley is a board-certified toxicologist with over 30 years of experience in the active practice of toxicology. She earned her degrees in Toxicology, an MS from the University of Arizona, and a PhD from the University of North Carolina at Chapel Hill, in collaboration with the laboratories of the NIEHS and US EPA. She is certified by the American Board of Toxicology (ABT) and is a Fellow of the Academy of Toxicological Sciences (ATS).

    Dr. Buckley’s diversity of professional experience as a toxicologist is reflected in her work spanning basic and applied toxicology research and risk assessment in the industrial chemical, agrochemical, and pharmaceutical industries. As a Vice President at Eli Lilly & Company, she was responsible for the design and execution of nonclinical safety assessment programs as well as for nonclinical aspects of global regulatory submissions and interactions for drugs in the development and commercialization phases. Dr. Buckley has authored the pharmacology/toxicology sections of numerous regulatory documents, including briefing documents, INDs/IMPDs, BLAs/NDAs, investigator brochures, annual reports, as well as safety information on product labels/package inserts.

    Her contributions to the profession of toxicology include service on the Boards of the ABT and the ATS (past President) and on the Councils of the ACT (past President) and the SOT.

Registration Fees:

Seminar registration is restricted to single person use only. Please note that all eLearning sales are final. No cancellations or refunds will be allotted after payment is processed.

The Regulatory and Nonclinical Considerations for the Development of CNS/Neurology Therapeutics eLearning seminar content will only be available until December 31, 2026.

Registration Type Set/Module 1–4
ACT Member $225
ACT Student/Transitional/Postdoctoral Researcher Member $125
Nonmember $350

*Fees are assessed according to membership status at the time of purchase. There are no exceptions and no refunds after payment has been processed.